Key result
Antisense oligodeoxynucleotides represent a promising class of antiviral agents that inhibit viral gene expression through both sequence-specific and non-sequence-specific mechanisms.
Why the study?
Do antisense oligodeoxynucleotides inhibit viral replication in viruses such as HIV-1 and HSV?
Do antisense oligodeoxynucleotides inhibit viral replication in viruses such as HIV-1 and HSV?
Antisense oligodeoxynucleotides represent a promising class of antiviral agents capable of inhibiting viral replication through sequence-specific and non-specific mechanisms.
Does not support clinical use of antisense antivirals; leaves open their promise pending randomized trials.
Antisense oligodeoxynucleotides are a promising new class of antiviral agent. Because they bind in a sequence-specific manner to complementary regions of mRNA, oligos can inhibit gene expression in a sequence-specific manner. The ‘antisense’ approach has been used successfully to block cellular expression and replication of several viruses including Human Immunodeficiency Virus-1 (HIV-1), and Herpes Simplex Virus (HSV). However, the antiviral effect of oligodeoxynucleotides is not limited to sequence-specific inhibition of gene expression. Non sequence-specific effects are frequently observed, presumably as a result of their properties as polyanions. Occasionally (e.g. for HIV-1) these non sequence-specific effects are also therapeutic. The prospects for antisense oligodeoxynucleotide therapy for viral disease are discussed.
No takes yet. Share an insight, caveat, or question.
Tonkinson et al. (1993) conducted a review in Viral diseases (e.g., HIV-1, HSV). Antisense oligodeoxynucleotides was evaluated. Antisense oligodeoxynucleotides represent a promising class of antiviral agents that inhibit viral gene expression through both sequence-specific and non-sequence-specific mechanisms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: